In vitro and in vivo studies on rats have shown that exposure to rivaroxaban increases when they are administered imatinib because of CYP2J2, CYP3A4, BCRP, and P-gp inhibition and decreases when they are administered sunitinib due to BCRP induction, which may impact cancer-associated venous thromboembolism management [56]. Here, CYP3A4 is linked to cancer.